SI1114033T1 - 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors - Google Patents

4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Info

Publication number
SI1114033T1
SI1114033T1 SI9930672T SI9930672T SI1114033T1 SI 1114033 T1 SI1114033 T1 SI 1114033T1 SI 9930672 T SI9930672 T SI 9930672T SI 9930672 T SI9930672 T SI 9930672T SI 1114033 T1 SI1114033 T1 SI 1114033T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroquinolines
carboxyamino
methyl
cetp inhibitors
cetp
Prior art date
Application number
SI9930672T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael Paul Deninno
Christian James Mularski
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SI1114033T1 publication Critical patent/SI1114033T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9930672T 1998-09-17 1999-09-10 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors SI1114033T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10092998P 1998-09-17 1998-09-17
EP99940421A EP1114033B1 (fr) 1998-09-17 1999-09-10 4-carboxyamino-2-methyl-1,2,3,4-tetrahydro-quinoleine utilisees comme inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp)
PCT/IB1999/001529 WO2000017166A1 (fr) 1998-09-17 1999-09-10 4-carboxyamino-2-methyl-1,2,3,4-tetrahydro-quinoleine utilisees comme inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp)

Publications (1)

Publication Number Publication Date
SI1114033T1 true SI1114033T1 (en) 2005-02-28

Family

ID=22282259

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930672T SI1114033T1 (en) 1998-09-17 1999-09-10 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Country Status (25)

Country Link
US (2) US6147090A (fr)
EP (1) EP1114033B1 (fr)
JP (1) JP3655193B2 (fr)
AR (1) AR021482A1 (fr)
AT (1) ATE277906T1 (fr)
AU (1) AU5439899A (fr)
BR (1) BR9913842A (fr)
CA (1) CA2344556A1 (fr)
CO (1) CO5150220A1 (fr)
DE (1) DE69920727T2 (fr)
DK (1) DK1114033T3 (fr)
DZ (1) DZ2889A1 (fr)
ES (1) ES2228086T3 (fr)
GT (1) GT199900149A (fr)
HN (1) HN1999000155A (fr)
MA (1) MA26687A1 (fr)
MY (1) MY121838A (fr)
PA (1) PA8481501A1 (fr)
PE (1) PE20001048A1 (fr)
PT (1) PT1114033E (fr)
SI (1) SI1114033T1 (fr)
SV (1) SV1999000149A (fr)
TN (1) TNSN99172A1 (fr)
TW (1) TWI232859B (fr)
WO (1) WO2000017166A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
WO2002078625A2 (fr) * 2001-03-28 2002-10-10 Pharmacia Corporation Combinaisons therapeutiques pour signes cardiovasculaires et inflammatoires
SE0101161D0 (sv) 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
KR20040015746A (ko) * 2001-06-21 2004-02-19 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제
CA2450957A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
SK15742003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465854A4 (fr) * 2001-12-19 2005-06-08 Atherogenics Inc Derives de chalcone et leur utilisation dans le traitement de maladies
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2003063833A1 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
WO2003063868A1 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
KR100634195B1 (ko) 2002-08-30 2006-10-16 니뽄 다바코 산교 가부시키가이샤 디벤질아민 화합물 및 그 의약 용도
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
BR0315041A (pt) 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
ES2263015T3 (es) * 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2753318A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Derives pyrroliques substitues
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
CN101342162A (zh) 2003-09-26 2009-01-14 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
JP4773969B2 (ja) 2003-10-08 2011-09-14 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
SI1732933T1 (sl) * 2004-03-26 2008-10-31 Lilly Co Eli Spojine za zdravljenje dislipidemije
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
WO2006004903A2 (fr) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
SG163577A1 (en) 2004-12-03 2010-08-30 Schering Corp Substituted piperazines as cb1 antagonists
WO2006069162A1 (fr) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
WO2006082518A1 (fr) 2005-02-03 2006-08-10 Pfizer Products Inc. Compositions pharmaceutiques a efficacite amelioree
CN101146776A (zh) 2005-02-24 2008-03-19 米伦纽姆医药公司 治疗炎性疾病的pgd2受体拮抗剂
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CA2637565A1 (fr) 2006-01-18 2007-07-26 Schering Corporation Modulateurs de recepteurs de cannibinoides
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
ATE500222T1 (de) * 2006-02-07 2011-03-15 Hoffmann La Roche Benzamid- und heteroarenderivate als cetp- inhibitoren
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
WO2007107843A1 (fr) * 2006-03-22 2007-09-27 Pfizer Products Inc. Procédés de traitement avec des inhibiteurs de la cetp
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2008010087A2 (fr) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
WO2008129951A1 (fr) 2007-04-13 2008-10-30 Kowa Company, Ltd. Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
KR20100051625A (ko) 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Ｃｂ1 길항제로서의 치환된 피페라진
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
EP2217596B8 (fr) 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de l'activite du gpr 119
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
CA2730593A1 (fr) 2008-07-16 2010-01-21 Schering Corporation Derives heterocycliques bicycliques et leur utilisation comme modulateurs du gpr119
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
WO2010075269A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés de pyrimidine en tant que modulateurs de rcpg pour une utilisation d'un traitement de l'obésité et du diabète
AU2009330208A1 (en) 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP2414348B1 (fr) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Dérivés de pipéridine et de pipérazine bicycliques en tant que modulateurs de rcpg pour le traitement de l'obésité, du diabète et d'autres troubles métaboliques
CA2778684A1 (fr) 2009-10-29 2011-05-05 Schering Corporation Derives de piperidine bicycliques pontes et leurs procedes d'utilisation
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2020081678A1 (fr) * 2018-10-17 2020-04-23 Duke University Inhibiteurs de la quinone réductase 2 destinés à être utilisés en tant qu'agents neuroprotecteurs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
ATE277906T1 (de) 2004-10-15
PA8481501A1 (es) 2001-12-14
EP1114033A1 (fr) 2001-07-11
AR021482A1 (es) 2002-07-24
US6395751B1 (en) 2002-05-28
DE69920727T2 (de) 2006-03-09
ES2228086T3 (es) 2005-04-01
DZ2889A1 (fr) 2003-12-15
TWI232859B (en) 2005-05-21
DE69920727D1 (en) 2004-11-04
US6147090A (en) 2000-11-14
HN1999000155A (es) 2000-01-12
DK1114033T3 (da) 2004-12-20
AU5439899A (en) 2000-04-10
TNSN99172A1 (fr) 2005-11-10
CO5150220A1 (es) 2002-04-29
WO2000017166A1 (fr) 2000-03-30
GT199900149A (es) 2001-03-03
BR9913842A (pt) 2001-06-12
EP1114033B1 (fr) 2004-09-29
JP2002526477A (ja) 2002-08-20
SV1999000149A (es) 2000-07-06
MY121838A (en) 2006-02-28
MA26687A1 (fr) 2004-12-20
JP3655193B2 (ja) 2005-06-02
CA2344556A1 (fr) 2000-03-30
PT1114033E (pt) 2004-12-31
PE20001048A1 (es) 2000-10-17

Similar Documents

Publication Publication Date Title
IL173393A0 (en) 4-carboxyamino-2- substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
SI1114033T1 (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
IL141388A0 (en) 4-amino substituted-2- substituted 1,2,3,4- tetrahydroquinolines as cetp inhibitors
HRP20010454B1 (en) 1,2-annelated quinoline derivatives
ZA200007593B (en) Quinoline Derivatives.
ZA982771B (en) Substituted 3-Cyano Quinolines.
IL143782A0 (en) Quinoline derivatives
PL343420A1 (en) Quinoline derivatives
PL355892A1 (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
SG102603A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
HK1035716A1 (en) Quinoline derivatives
SI1114031T1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors